The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands.
The aim of this study was to calculate the costs of the current initial treatment of acute myeloid leukemia. Resource use was collected for 202 patients who started with intensive chemotherapy in 2008 or 2009. The costs of the first induction course were significantly higher than the costs of the second induction course. Allogeneic transplantation from a matched unrelated donor was significantly more expensive than the other consolidation treatments. In-hospital stay was the major cost driver in the treatment of AML. Research regarding possibilities of achieving the same or better health outcome with lower costs is warranted.
Institute for Medical Technology Assessment/Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. leunis@bmg.eur.nl
Annemieke
A
Leunis
Hedwig M
HM
Blommestein
Peter C
PC
Huijgens
Nicole M A
NM
Blijlevens
Mojca
M
Jongen-Lavrencic
Carin A
CA
Uyl-de Groot
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000191:economics; D060830:Consolidation Chemotherapy / Q000191:economics; D017048:Health Care Costs / Q000706:statistics & numerical data; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D060828:Induction Chemotherapy / Q000191:economics; D015470:Leukemia, Myeloid, Acute / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D060046:Maintenance Chemotherapy / Q000191:economics; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000191:economics*; D009426:Netherlands / Q000453:epidemiology; D018714:Radiotherapy, Adjuvant / Q000191:economics; D014184:Transplantation, Homologous / Q000191:economics